Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 1/20 | 1.00 |
| ▸ | CA12 | O43570 | 17/20 | 0.70 |
| ▸ | CA9 | Q16790 | 16/20 | 0.70 |
| ▸ | CA1 | P00915 | 2/20 | 0.64 |
| ▸ | CA2 | P00918 | 5/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6958970 | 0.83 | CA12 (0.71) | ELANECA12CA9CA1CA2 | |
| SCHEMBL5120710 | 0.83 | CA9 (0.72) | ELANECA12CA9CA1CA2 | |
| SCHEMBL1172438 | 0.82 | CA12 (1.00) | ELANECA12CA9CA1CA2 | |
| SCHEMBL30527996 | 0.82 | CA12 (1.00) | ELANECA12CA9CA1CA2 | |
| SCHEMBL9826952 | 0.82 | CA9 (0.73) | ELANECA12CA9CA2 | |
| SCHEMBL7281348 | 0.81 | CA12 (0.69) | ELANECA12CA9CA1CA2 | |
| SCHEMBL356403 | 0.81 | CA12 (0.69) | ELANECA12CA9CA2 | |
| SCHEMBL1101896 | 0.81 | CA12 (1.00) | ELANECA12CA9CA1CA2 | |
| SCHEMBL7290946 | 0.81 | CA12 (0.69) | ELANECA12CA9CA1CA2 | |
| SCHEMBL7290973 | 0.81 | CA12 (0.69) | ELANECA12CA9CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0483928-A1 | 2-Saccharinylmethyl aryl carboxylates useful as proteolytic enzyme inhibitors and compositions and method of use | STERLING WINTHROP INC. (US) | 1992-05-06 | — | — | EP | claimed |
| US-10364263-B2 | Cyclic phosphates and cyclic phosphoramidates for the treatment of neurologic disorders | Retrophin, Inc. (US) | 2019-07-30 | — | — | US | disclosed |
| US-20180362564-A1 | CYCLIC PHOSPHATES AND CYCLIC PHOSPHORAMIDATES FOR THE TREATMENT OF NEUROLOGIC DISORDERS | Retrophin, Inc. | 2018-12-20 | — | — | US | disclosed |
| EP-3386995-A1 | CYCLIC PHOSPHATES AND CYCLIC PHOSPHORAMIDATES FOR THE TREATMENT OF NEUROLOGIC DISORDERS | Retrophin, Inc. (US) | 2018-10-17 | — | — | EP | disclosed |
| US-10058534-B2 | Benzothiophene derivatives and compositions thereof as selective estrogen receptor degraders | NOVARTIS AG (CH) | 2018-08-28 | — | — | US | disclosed |
| US-20180169063-A1 | BENZOTHIOPHENE DERIVATIVES AND COMPOSITIONS THEREOF AS SELECTIVE ESTROGEN RECEPTOR DEGRADERS | NOVARTIS AG (CH) | 2018-06-21 | — | — | US | disclosed |
| US-9931317-B2 | Benzothiophene derivatives and compositions thereof as selective estrogen receptor degraders | NOVARTIS AG (CH) | 2018-04-03 | — | — | US | disclosed |
| EP-2958907-B1 | BENZOTHIOPHENE DERIVATIVES AND COMPOSITIONS THEREOF AS SELECTIVE ESTROGEN RECEPTOR DEGRADERS | NOVARTIS AG (CH) | 2018-02-28 | — | — | EP | disclosed |
| US-20170174600-A1 | 2,5-DIALKYL-4-H/HALO/ETHER-PHENOL COMPOUNDS | TANSNA THERAPEUTICS, INC. | 2017-06-22 | — | — | US | disclosed |
| US-20170174600-A1 | 2,5-DIALKYL-4-H/HALO/ETHER-PHENOL COMPOUNDS | TANSNA THERAPEUTICS, INC. | 2017-06-22 | — | — | US | disclosed |
| EP-0471756-A1 | SACCHARIN DERIVATIVES USEFUL AS PROTEOLYTIC ENZYME INHIBITORS AND PREPARATION THEREOF. | STERLING WINTHROP INC (US) | 1992-02-26 | — | — | EP | disclosed |
| US-5001115-A | Prodrugs of biologically active hydroxyaromatic compounds | UNIVERSITY OF FLORIDA (US) | 1991-03-19 | — | — | US | disclosed |
| WO-1990013549-A1 | SACCHARIN DERIVATIVES USEFUL AS PROTEOLYTIC ENZYME INHIBITORS AND PREPARATION THEREOF | STERLING WINTHROP INC. (US) | 1990-11-15 | — | — | WO | disclosed |
| US-4198413-A | HYPOTENSIVE AGENTS | MERCK & CO., INC. (US) | 1980-04-15 | — | — | US | disclosed |
| US-4143146-A | HYPOTENSIVE AGENTS | MERCK & CO., INC. (US) | 1979-03-06 | — | — | US | disclosed |
| US-4058530-A | PHENYLALANINE, ANTIHYPERTENSIVE | MERCK & CO., INC. (US) | 1977-11-15 | — | — | US | disclosed |
| US-4051169-A | HYPOTENSIVE AGENTS | MERCK & CO., INC. (US) | 1977-09-27 | — | — | US | disclosed |
| US-4038411-A | ANTIHYPERTENSIVE AMINO ACID ESTERS | MERCK & CO., INC. (US) | 1977-07-26 | — | — | US | disclosed |
| US-3988341-A | Esterification process | MERCK & CO., INC. (US) | 1976-10-26 | — | — | US | disclosed |
| US-3983138-A | HYPOTENSIVES | MERCK & CO., INC. (US) | 1976-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10058534-B2 | Benzothiophene derivatives and compositions thereof as selective estrogen receptor degraders | ESR1, CYP19A1, GPER1 | ELANE 1292/4885CA12 3871/4885CA9 3377/4885 |
| US-20180362564-A1 | CYCLIC PHOSPHATES AND CYCLIC PHOSPHORAMIDATES FOR THE TREATMENT OF NEUROLOGIC DISORDERS | PPA1, PRPS1, PYGB | ELANE 3413/4885CA12 4207/4885CA9 3422/4885 |
| US-20170174600-A1 | 2,5-DIALKYL-4-H/HALO/ETHER-PHENOL COMPOUNDS | COMT, DDT, TYR | ELANE 3200/4885CA12 3955/4885CA9 3445/4885 |
| US-20180169063-A1 | BENZOTHIOPHENE DERIVATIVES AND COMPOSITIONS THEREOF AS SELECTIVE ESTROGEN RECEPTOR DEGRADERS | ESR1, CYP19A1, GPER1 | ELANE 1292/4885CA12 3871/4885CA9 3377/4885 |
| US-10364263-B2 | Cyclic phosphates and cyclic phosphoramidates for the treatment of neurologic disorders | PPA1, PRPS1, PYGB | ELANE 3413/4885CA12 4207/4885CA9 3422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.